Recently, Zhejiang Haizhou Pharmaceutical Co. Ltd and Netsun (002095.SZ) signed a cooperation agreement to promote private enterprises to build online trading platform, enterprise sales strategy, and choose to promote enterprise financial strategy of online sales.
Online is an improved type of innovation of enterprise sales, and finance is the disruptive innovation of enterprise sales; online is the basis of finance; and the financial online is not only an important strategy of national development strategy in 13th Five-Year, but also an important strategic China manufacturing 2025.
Zhejiang Haizhou Pharmaceutical Co. Ltd. in the technical guidance and help the Netsun, gradually promote the enterprise sales online and financial, to promote the enterprise out of a "Internet plus" and "supply side reform" of the transformation and upgrading of the road.
Company profile
Zhejiang Haizhou Pharmaceutical Co., Ltd. (hereinafter referred to as "Haizhou pharmaceutical"), formerly known as the pharmaceutical factory (state-owned enterprises), founded in 1968, August 1997 for the restructuring renamed Zhejiang Jianfenghaizhou Pharmaceutical Co. Ltd., May 2014 renamed Zhejiang Haizhou Pharmaceutical Co. ltd.. Haizhou pharmaceutical is an innovative pharmaceutical pharmaceutical chemical field, located in state-level chemical raw materials base Zhejiang chemical raw materials base in coastal zone, the total assets of nearly 300 million yuan, covering an area of 131782 square meters (about 200 acres).
Haizhou pharmaceutical which belongs to the national key high-tech enterprise, has a research and development center of high-tech enterprises at the provincial level, the provincial technical center, mainly engaged in pharmaceutical raw materials and pharmaceutical intermediates production, including cough medicine raw materials series, silicone series, contrast agent series of pharmaceutical raw materials and intermediates. In 2013, R & D funds accounted for more than 4% of sales revenue, as of now, a total of 8 authorized invention patents, 8 patents in the review.
Haizhou pharmaceutical with good quality management system, now has 7 API (potassium guaiacolsulfonate, guaifenesin, taurine, pyrazinamide, anastrozole, irsogladine maleate and Azasetron hydrochloride) through the national GMP certification, which guaiphenesin also passed the official site inspection FDA the European Union, EDQM, KFDA and FDA in Mexico, South korea.
Haizhou pharmaceutical is committed to the international standard EHS system, again in 2015 through the acceptance of clean production and safety standards sponsored by the relevant departments, won the safety production standardization of two enterprises (medical) certificate, is a qualified supplier of international and domestic top pharmaceutical companies, the export ratio of more than 50%.